Home » Topics » BioWorld Science

BioWorld Science
RSS

Cyanovirin-N selected for high priority development by the National Cancer Institute

July 26, 1996

CHAM3 induces clinical and biological improvement in HIV patients

July 26, 1996

ZY-1 demonstrates therapeutic promise in HIV patients

July 26, 1996

TAR-PAK-140: University of Alberta's anti-HIV vector

July 26, 1996

Mulsal N shows significant CD4 cell count increases in trial

July 26, 1996

Virulizin enters phase I/II for drug-resistant HIV-related Kaposi's sarcoma

July 26, 1996

Columbia Laboratories' SPC3 undergoes phase I/II trials

July 26, 1996

Allophenylnorstatine HIV protease inhibitors described

July 26, 1996

Sequus licenses liposome-CD4 technology

July 26, 1996

Gilead Science's sulfone HIV protease inhibitors

July 26, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 7, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 7, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...